Radioisotope manufacturer International Isotopes has posted increased revenue for its 2023 first quarter.
For the period (end-March 31), the company reported revenue of $3.1 million, up 10% from $2.8 million in the first quarter of 2022. It attributed the uptick to increases in its radiochemical and nuclear medicine segments. However, the firm also had a net loss of $148,054, compared with net income of $1.2 million for the same period in 2022.
The company posted a revenue increase of 8% in its radiochemical products segment for the period compared with the same period last year, which it attributed to an increase in sales of its sodium iodide I-131 drug. It also reported a revenue increase of 16% from its nuclear medicine products segment compared to the first quarter of 2022.
